TOKYO, April 23 (Reuters) - Japanese stocks rose on
Thursday, as sellers covered their positions after Wall Street
shares rebounded overnight on the promise of more U.S.
government aid to ease the economic pain inflicted by the
coronavirus pandemic.
The Nikkei share average .N225 rose 0.67% to 19,265.95
after three straight sessions of losses. The broader Topix
.TOPX gained 0.53% to 1,414.30.
Among the top gainers were shares that have been badly hit
so far this year, including advertisement firm Dentsu Group
4324.T , retailer J.Front Retailing 3086.T and oil
development firm Inpex 1605.T . They rose 4.8%, 4.4%, 4.2%
respectively.
Shares of some companies related to the semi-conductor
industry also jumped after their U.S. peers gained sharply, with
the Philadelphia Semiconductor index .SOX surging 5.9% in its
biggest one-day leap since April 6.
Fanuc Corp 6954.T rose 3.4%, while Alps Alpine 6770.T
gained 2.8%.
Transport equipment companies .ITEQP.T rose 1%, with Honda
Motor Co Ltd 7267.T gaining 2.3%.
The index of Mothers start-up shares .MTHR rose 3.3%,
erasing losses made earlier this week.
CyberAgent 4751.T climbed 8.6% after the company reported
strong growth in quarterly profit on brisk gaming business.
On the other hand, drugmaker Eisai lost 7.4% after Biogen
Inc BIIB.O on Wednesday delayed the filing for marketing
approval of its experimental Alzheimer's disease drug developed
jointly with Eisai.
Biogen said it needed more time to prepare the data before
submission.
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Japanese shares rise after 3 days of falls; Eisai slumps on drug delay
Published 23/04/2020, 04:24
Japanese shares rise after 3 days of falls; Eisai slumps on drug delay
Latest comments
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2024 - Fusion Media Limited. All Rights Reserved.